Our study supports that aBRAF mCRC is indeed a distinct subtype of colorectal cancer with the most notable findings of ctDNA analysis, confirming that aBRAF (BRAF class II, III, unclassified variants) and co-occurrence with KRAS/NRAS mutations was increased at baseline and especially in patients predicted to have prior anti-EGFR exposure, in contrast to BRAFV600E. Here, NRAS is linked to colorectal cancer.